Dapagliflozin
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. See also [https://en.wikipedia.org/wiki/Dapagliflozin Dapagliflozin]. | Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. See also [https://en.wikipedia.org/wiki/Dapagliflozin Dapagliflozin]. | ||
| - | Dapagliflozin is used along with diet, exercise, and usually with other glucose lowering medications, to improve glycaemic control in adults with type 2 diabetes and to reduce the risk of hospitalization for heart failure among adults with type 2 diabetes and known cardiovascular disease or other cardiovascular risk factors (including high blood pressure, high cholesterol, and smokers). Dapagliflozin, in addition to other SGLT2 | + | Dapagliflozin is used along with diet, exercise, and usually with other glucose lowering medications, to improve glycaemic control in adults with type 2 diabetes and to reduce the risk of hospitalization for heart failure among adults with type 2 diabetes and known cardiovascular disease or other cardiovascular risk factors (including high blood pressure, high cholesterol, and smokers). Dapagliflozin, in addition to other [[Sodium/glucose cotransporter]] (SGLT2) inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults.<ref name="a14">PMID:32970396</ref><ref name="a15">PMID:30990260</ref> |
<scene name='10/1001152/Cv/2'>Human SGLT2-MAP17 complex with Dapagliflozin</scene> ([[8hez]]). | <scene name='10/1001152/Cv/2'>Human SGLT2-MAP17 complex with Dapagliflozin</scene> ([[8hez]]). | ||
Current revision
| |||||||||||
References
- ↑ Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. PMID:32970396 doi:10.1056/NEJMoa2024816
- ↑ Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. PMID:30990260 doi:10.1056/NEJMoa1811744
